Seattle startup adyn raised a $2.5 million seed round co-led by Lux Capital and M13. The company plans to launch its flagship birth control optimization test later this year and currently has a waitlist for early access. Adyn’s test analyzes hormone levels to identify potential side effects for women — from acne to blood clots — caused by different methods of birth control. The flagship product for consumers will be an at-home test kit; users receive data and personalized recommendations through adyn’s platform and telemedicine appointments. The company then sends prescriptions directly to customers.